Phase 1 Trial of Preoperative, Short-Course Carbon-Ion Radiotherapy for Patients With Resectable Pancreatic Cancer
|
|
- Douglas Preston
- 8 years ago
- Views:
Transcription
1 Phase 1 Trial of Preoperative, Short-Course Carbon-Ion Radiotherapy for Patients With Resectable Pancreatic Cancer Makoto Shinoto, MD 1,2 ; Shigeru Yamada, MD, PhD 1 ; Shigeo Yasuda, MD, PhD 1 ; Hiroshi Imada, MD, PhD 1 ; Yoshiyuki Shioyama, MD, PhD 3 ; Hiroshi Honda, MD, PhD 2 ; Tadashi Kamada, MD, PhD 1 ; Hirohiko Tsujii, MD, PhD 1 ; Hiromitsu Saisho, MD, PhD 4 ; and Working Group for Pancreas Cancer BACKGROUND: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue. METHODS: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT. RESULTS: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively. CONCLUSIONS: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity. Cancer 2013;119: VC 2012 American Cancer Society. KEYWORDS: preoperative, short course, carbon-ion radiotherapy, pancreatic cancer, phase 1. INTRODUCTION The number of deaths from pancreatic cancer in Japan exceeds 26,000 per year, and the incidence is increasing year by year. 1 Pancreatic cancer is the fifth leading cause of cancer death, and it is considered 1 of the most lethal cancers in Japan. Complete surgical resection has traditionally been considered the only curative treatment, but high rates of local and systemic failure persist in patients who undergo curative resections, and the 5-year survival rate is <20%. 2,3 In an effort to improve outcomes, multidisciplinary approaches have been used. Previous randomized trials have suggested the prominent role of chemotherapy as adjuvant treatment. 2,4,5 Thus, in Japan, the use of gemcitabine as adjuvant treatment in patients with resectable pancreatic cancer is recommended in terms of efficacy and safety. 6 Nonetheless, the role of neoadjuvant treatment is still controversial. Recent prospective and retrospective studies suggest that the combination of preoperative chemoradiation and surgery improves survival duration; however, randomized controlled trials have not been performed In terms of strategy for local tumor control, radiotherapy may have an important role, because local recurrence rates remain high after surgery alone (range, 40%-80%). 2,11-13 Carbon-ion radiotherapy (CIRT) offers the potential advantage of improved dose localization and enhanced biologic effect. 14 Preoperative CIRT is expected to be effective in eliminating the retroperitoneal microinvasion of malignant cells, which cannot be removed by surgery. When a combination of CIRT and surgery is used to maximize local tumor control, patients with resectable pancreatic cancer may benefit in terms of improved overall survival. The objective of the current study was to investigate the safety of preoperative, short-course CIRT for patients with resectable pancreatic cancer. MATERIALS AND METHODS Patient Eligibility Patients were eligible if they had radiographically assessable, radically resectable pancreatic cancer without involvement of the hepatic artery, celiac trunk, or superior mesenteric artery and if they were without evidence of metastatic disease. Eligible patients were aged <80 years and had an Eastern Cooperative Oncology Group performance status of <2 and Corresponding author: Makoto Shinoto, MD, Hospital of Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1, Anagawa, Inage-ku, Chiba, Japan; Fax: (011) ; shinoto@nirs.go.jp 1 Hospital of Research Center for Charged Particle Therapy, National Institute of Radiological Sciences. Chiba, Japan; 2 Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 3 Department of Heavy Particle Therapy and Radiation Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 4 Department of Internal Medicine and Clinical Oncology, Kaken Hospital, Chemotherapy Research Institute, Chiba, Japan DOI: /cncr.27723, Received: March 20, 2012; Revised: May 23, 2012; Accepted: May 31, 2012, Published online June 28, 2012 in Wiley Online Library (wileyonlinelibrary.com) Cancer January 1,
2 Figure 1. These computed tomography images illustrate dose distribution for treatment planning. Colored isodose lines indicate 95%, 90%, 70%, 50%, 30%, 20%, and 10% dose areas (from inside to outside). adequate organ function to tolerate surgery. Patients were excluded if they had received prior therapy for pancreatic cancer or previous radiotherapy to the upper abdomen and if they had a concomitant malignancy, active inflammatory bowel disease, active gastric/duodenal ulcer, mental disorder, or other severe concurrent disease. The treatment protocol for the current study was reviewed and approved by the National Institute of Radiological Sciences Ethics Committee of Human Clinical Research, and all patients signed an informed consent form before the initiation of therapy. Carbon-Ion Radiotherapy All patients were positioned in customized cradles (Moldcare; Alcare, Tokyo, Japan) and immobilized with a low-temperature thermoplastic shell (Shellfitter; Kuraray, Osaka, Japan). A set of 2.5-mm-thick or 5-mm-thick computed tomography (CT) images was taken for treatment planning with the immobilization devices under respiratory gating. Three-dimensional treatment planning of CIRT was performed using the HIPLAN software program (National Institute of Radiological Sciences, Chiba, Japan). 15,16 Field arrangements generally were designed using a 3-field plan. The clinical target volume was defined as the gross tumor volume with a 5-mm margin and the locoregional elective lymph node and neuroplexus region. The locoregional elective lymph node region included the celiac, superior mesenteric, peripancreatic, portal, and para-aortic region for pancreatic head cancers and the splenic region for pancreatic body and tail cancers. The planning target volume included the clinical target volume with a 5-mm margin for possible positioning Table 1. Dose-Escalation Schedule and the Number of Treated Patients Dose Level CIRT, GyE No. of Patients No. who Underwent Resection Abbreviations: CIRT, carbon-ion radiotherapy; GyE, gray equivalents. errors, respecting anatomic boundaries such as stomach, duodenum, small intestine, and transverse colon. In patients who had tumors located close to critical organs, the margins were reduced accordingly. The tumor extent was evaluated by CT, magnetic resonance imaging (MRI), and positron emission tomography (PET). A typical dose distribution is illustrated in Figure 1. Patients received CIRT out daily 4 days per week (Tuesday through Friday). In a dose-escalated study, we started irradiation at a dose of 30 Gray equivalents (GyE) in 8 fractions, fixed the irradiation fractions, and increased the radiation dose by increments of 5%. Doses of carbon ion were expressed in photon equivalent doses, which were defined as the physical doses multiplied by the relative biologic effectiveness of the carbon ions. 16 The doseescalation schedule is provided in Table 1. Surgery All patients underwent restaging CT scans to evaluate resectability before surgery. Resectable disease was defined 46 Cancer January 1, 2013
3 Preoperative CIRT for Pancreatic Cancer/Shinoto et al Figure 2. The treatment schema is illustrated for preoperative carbon-ion radiotherapy (CIRT) and surgery. Patients received CIRT in 8 fixed fractions (8fr.) over 2 weeks and underwent surgery 2 to 4 weeks after the completion of CIRT. as the absence of distant metastasis and no infiltration of main arteries, such as the common hepatic, celiac, and superior mesenteric arteries. Invasion of the portal vein, superior mesenteric vein, or splenic vein was not a contraindication to resection, and these vessels were resected if necessary. Patients were to undergo surgical resection 2 to 4 weeks after the completion of CIRT (Fig. 2). Patient Evaluation for Toxicity and Response Acute reactions of normal tissues after CIRT were classified according to National Cancer Institute Common Toxicity Criteria (version 2.0) within 90 days of the start of CIRT. Late reactions were classified according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scoring system or Late Effects in Normal Tissues (LENT) Subjective, Objective, Management, and Analytic scales scoring system. A dose-limiting toxicity (DLT) was defined as any grade 3 or greater acute toxicity. Toxicities that were not caused by CIRT were not classified as DLTs, for example, cholangitis from a blocked biliary stent and symptoms related to tumor progression, such as pain or bowel obstruction. Patients were evaluable for DLT regardless of whether they underwent surgery after preoperative CIRT. Patient cohorts consisted of a minimum of 3 patients at each dose level. If no DLT was observed in the initial 3 patients, then the dose was escalated in successive cohorts. If DLT was observed in 1 or 2 of the initial 3 patients at a given level, then 3 additional patients were evaluated at the same level. If only 1 or 2 of these patients experienced DLT, then the next level of dose schedule would begin enrollment. If 3 or more patients experienced DLT at a given level, then the previous level would be considered the maximally tolerated dose (MTD). Tumor response was determined by comparing pre- CIRT and post-cirt CT scans and was assessed using Response Evaluation Criteria in Solid Tumors. A complete response (CR) was defined as disappearance of the primary tumor, and a partial response (PR) was defined as a decrease 30% in the greatest dimension of the primary tumor. The response rate was defined as the percentage of patients achieving either a CR or a PR. Progressive disease was defined as an increase 20% in the greatest dimension of the primary tumor. Stable disease was identified as a tumor response not definable as CR, PR, or progressive disease. Furthermore, histologic response to preoperative CIRT was judged by an assessment of cytologic change in conjunction with quantification of the amount of viable residual carcinoma cells. A grade 0 treatment response was defined as the destruction of no tumor cells, a grade 1 response was defined as the destruction of less than twothirds of tumor cells, a grade 2 response was defined as the destruction of greater than two-thirds of tumor cells, and a grade 3 response indicated the presence of no viable tumor cells. Follow-Up Patients were followed by CT, MRI, or PET scans every 3 to 6 months. Local recurrence was defined in terms of lesions occurring in the planning target volume based on CT, MRI, or PET scans. The absence of local recurrence was described as local control. Recurrent disease was diagnosed by imaging studies, and biopsy confirmation was not obtained. Statistical Analysis The primary endpoint of this study was to evaluate acute reactions in normal tissues that determine the MTD and response rate of preoperative CIRT. The secondary endpoint was to assess the rates of late toxicity, local control, and overall survival. Local control and overall survival were calculated from the first day of CIRT using the Kaplan-Meier method. RESULTS Patient Characteristics Twenty-nine patients were recruited into this study between April 2003 and December Three patients were ineligible because of liver metastases that became obvious before CIRT. Thus, 26 patients were enrolled in the study. The characteristics of the eligible patients are listed in Table 2. The median age was 66 years (range, years). The Eastern Cooperative Oncology Group performance status was 0 in 20 patients and 1 in 6 patients. The median serum CA 19-9 level was U/mL (range, ,200 U/mL). Three to 6 patients were treated at each dose level until the MTD was reached. Cancer January 1,
4 Toxicity Acute and late toxicities are listed in Table 3. All patients completed the scheduled treatment course without treatment breaks, and no DLT was observed. One patient developed acute grade 3 toxicity, which was a liver abscess caused by intraportal chemotherapy for liver metastases after surgery; however, it was not classified as a DLT, because we judged that it was not caused by CIRT. One patient developed late grade 4 toxicity, consisting of deterioration of liver function because of portal vein stenosis 3 months after pancreaticoduodenectomy with combined resection of the long segment of the superior mesentericsplenic-portal vein confluence. No other serious adverse effects were observed. Table 2. Patient Characteristics at Baseline Characteristic All patients 26 Sex Men 15 Women 11 Median age (range), y 66 (40-79) ECOG PS Tumor location Head 16 Body-tail 10 Clinical stage: UICC 6th IIA 15 IIB 11 Surgery PD 15 DP 5 TP 1 Bypass 2 No surgery 3 No. of Patients Abbreviations: DP, distal pancreatectomy; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, pancreatoduodenectomy; TP, total pancreatectomy; UICC 6th, International Union Against Cancer TNM Classification of Malignant Tumors, 6th edition. Response Regarding local response, 1 patient achieved a PR, the remaining 25 patients had stable disease, and no patients had progressive disease at the completion of CIRT. All 26 patients completed all planned CIRT. The radiographic findings of local effects for the 26 patients at restaging before surgery were stable disease in 25 patients and a PR in 1 patient. Twenty-one patients (81%) underwent resection, and no patient experienced a delay in planned surgery. The resections included 15 pancreaticoduodenectomies, 5 distal subtotal pancreatectomies, and 1 total pancreatectomy. Five patients did not undergo surgery, 4 because of metastatic progression and 1 because of refusal. No patient was had unresectable disease based on local tumor extension. The median time from the last day of CIRT to surgical resection was 20 days (range, days). Pancreatic ductal adenocarcinoma was confirmed in all resected patients. Nineteen of 21 patients (90%) underwent complete resection with no microscopic residual tumor (R0), and the other 2 patients had microscopically positive pancreatic transection margins (R1). One of the 2 patients who had a positive pancreatic cut-end margin, and according to an intraoperative rapid diagnosis, was believed to require total pancreatectomy to achieve radical resection, but this was not done because of her advanced age. Although she experienced regional recurrence after adjuvant chemotherapy, she received definitive CIRT, and the disease was controlled. The other patient with positive pancreatic transection margins did not receive adjuvant therapy because of refusal. Nevertheless, he had no evidence of recurrence. The histologic characteristics of the 21 resection specimens are listed in Table 4. All tumor specimens revealed evidence of grade 1 or 2 treatment effects, indicating that there were no marked differences among the respective dose levels. The median follow-up for survivors was 33.8 months. At last follow-up, 10 of 26 patients were alive, and 9 were disease free. Disease progression was noted in 19 patients, including 5 patients who did not undergo Table 3. Acute and Late Toxicities Acute Toxicities Late Toxicities NCI-CTC RTOG/EORTC Toxicity No No Skin Gastrointestinal Liver Portal vein Leakage Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; NCI-CTC, National Cancer Center Common Toxicity Criteria; RTOG, Radiation Therapy Oncology Group. 48 Cancer January 1, 2013
5 Preoperative CIRT for Pancreatic Cancer/Shinoto et al Table 4. Histologic Characteristics of the 21 Resection Specimens Dose Level No. of Patients Figure 4. Survival curves are illustrated for all 26 patients and for the patients who underwent surgical resection (n ¼ 21) versus those who did not undergo surgical resection (n ¼ 5). Figure 3. The local control rate is illustrated. resection. The pattern of initial disease progression was distant metastases in 17 patients (65%) and regional recurrence (defined as extra-ptv recurrence) in 2 patients (8%). None of the patients (100%) experienced local recurrence (Fig. 3). Two patients who experienced regional recurrence underwent salvage surgery or received definitive CIRT, and their disease was completely controlled. The median relapse-free survival was 6.2 months. The relapse-free survival rates at 1 year, 3 years, and 5 years were 40%, 23%, and 23%, respectively. The median overall survival was 18.6 months. The overall survival rates at 1 year, 3 years, and 5 years were 69%, 42%, and 42%, respectively, in all 26 patients. For the 21 patients who underwent surgery, the median overall survival has not yet been reached; the overall survival rates at 1 year, 3 years, and 5 years were 81%, 52%, and 52%, respectively (Fig. 4). This study did not reach the MTD, but dose level 5 was considered the recommended dose because of its prominent local control effect. DISCUSSION The objective of the current prospective study was mainly to evaluate the safety of preoperative, short-course CIRT in patients with resectable pancreatic cancer. In this doseescalation study, all patients completed the planned 2-week CIRT without developing severe toxicity. No patient experienced a decline in performance status or a delay in surgery. Spitz et al suggested that preoperative chemoradiation was more beneficial than postoperative chemoradiation. 17 Their experience indicated that pancreatic resection was too extensive and complex a procedure to enable the consistent postoperative delivery of standard-fractionation, adjuvant chemoradiation. Those authors reported that 24% of patients in their study did not receive postoperative adjuvant therapy because of delayed recovery from surgery. Other previous studies reported that preoperative chemoradiation did not increase the incidence of perioperative complications 18,19 ; however, grade 3 or greater toxicity was observed in approximately 20% to 40% of patients who received preoperative chemoradiation. 7,17,20 One meta-analysis of preoperative therapy for patients with resectable pancreatic cancer demonstrated that the rate of grade 3/4 toxicity was an estimated 26.3%. 21 In our current study, there was no grade 3/4 toxicity during preoperative CIRT. This is because carbon ions can be concentrated to a localized lesion, and damage to normal tissue is reduced. Our protocol comprised a short course received in only 8 fractions over 2 weeks, and the time to surgery also was short. There was little change, such as fibrosis after radiation, and the influence of the surgical maneuver was minimal. Conversely, pathologic evaluation did not reveal any CRs, and the pathologic response was not very prominent relative to the local control rate, because the time from the start of CIRT to surgery was too short for its adequate evaluation. In fact, 1 patient who had a positive dissected peripancreatic tissue margin had no evidence of local recurrence without any treatment. Cancer January 1,
6 A 2-month or 3-month protocol usually is adopted as preoperative therapy. Standard-fractionation, preoperative radiotherapy with concurrent chemotherapy is received for 5 to 6 weeks; then, patients undergo surgical resection 4 to 6 weeks after they complete chemoradiation. Preoperative chemoradiation may reduce the risk of local recurrence after surgery and contribute to prolonging median survival. Furthermore, this assessment may identify patients who present with rapid progressive or disseminated disease at restaging and, thus, have a very poor prognosis; for these patients, surgery is unlikely to provide any benefit. Conversely, there is the potential risk of tumor progression during neoadjuvant therapy; that is, patients who initially have resectable tumors may present with local or distant tumor progression at restaging, which may not have occurred in the setting of an initial tumor resection. Conversely, in preoperative, short-course CIRT, the risk of local or distant tumor progression during pretreatment is low because of the powerful local control achieved with CIRT. The high resection rate (81%) after preoperative treatment in our study was discriminative compared with reports from previous studies (range, 63%-73%). 21,22 Furthermore, since 2006, the resection rate has been 94% (15 of 16 patients). This may be associated with the development of multidetector CT or MRI technology, which improves the accuracy of predicting resectability or the detection of micrometastases to the liver. 23 Preoperative, short-course CIRT decreased the risk of postoperative local recurrence, although 65% of patients experienced distant metastases, and their prognosis was dismal; we considered that distant metastases already existed at the beginning of preoperative treatment in the form of microscopic metastases. In our study, concurrent or adjuvant chemotherapy was not permitted without obvious disease failure, although such treatments may be of further help in improving the prognosis of patients who had distant metastasis that became clinically evident after surgery. The combination of chemotherapy with CIRT may prolong the disease-free interval and survival, but a radical cure cannot be expected for patients who have microscopic metastatic disease, because current chemotherapy does not have enough power to eliminate pancreatic cancer cells completely. For patients who have microscopic metastases, it is important to avoid unnecessary surgery. For that reason, a more accurate diagnostic modality for pretreatment evaluation has to be established. If the probability of distant metastasis cannot be ruled out in patients who have resectable pancreatic cancer, then the treatment strategy may be switched from surgery to systemic chemotherapy or chemoradiation. In conclusion, the current results indicate that preoperative, short-course CIRT followed by early surgery is feasible and tolerable in patients who have potentially resectable pancreatic cancer. Although our sample size was too small to allow us to draw definitive conclusions, we believe it is reasonable to expect that a reduction in the risk of local recurrence will lead to an increase in the cure rate. The efficacy of this regimen will require investigation in a phase 2 study. FUNDING SOURCES This study was supported by the Research Project with Heavy Ions at the National Institute of Radiological Sciences-Heavy Ion Medical Accelerator in Chiba (NIRS-HIMC). CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. Matsuda T, Marugame T, Kamo KI, et al. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol. 2011;41: Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297: Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-72; discussion Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101: Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350: Yamaguchi K, Tanaka M. EBM-based clinical guidelines for pancreatic cancer 2009 from the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol. 2011;41: Hong TS, Ryan DP, Blaszkowsky LS, et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Int J Radiat Oncol Biol Phys. 2011;79: Sasson AR, Wetherington RW, Hoffman JP, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer. 2003;34: Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Ooncol Biol Phys. 2004;60: White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12: Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221: Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993;217: Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer local or hepatic? Hepatogastroenterology. 1993;40: Cancer January 1, 2013
7 Preoperative CIRT for Pancreatic Cancer/Shinoto et al 14. Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195: Kanai T, Furusawa Y, Fukutsu K, et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res. 1997;147: Kanai T, Endo M, Minohara S, et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44: Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. JClinOncol. 1997;15: Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127: Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169:71-77; discussion Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16: Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages [serial online]. PLoS Med. 2010;7:e Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20: Kim YE, Park MS, Hong HS, et al. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Radiology. 2009;250: Cancer January 1,
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationThe Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationPANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationCancer of the Pancreas
Cancer of the Pancreas James H. North Jr., M.D., F.A.C.S. It is estimated that in 2007, 37,170 patients will be diagnosed with cancer of the pancreas and 33,370 patients will die of this disease. 1 The
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationLocally advanced and bordeline forms of pancreatic cancer
19 May 2011 Locally advanced and bordeline forms of pancreatic cancer P r Pascal Hammel Pôle des Maladies de l Appareil Digestif Hôpital Beaujon, 92110 Clichy Université Paris VII, Denis Diderot pascal.hammel@bjn.aphp.fr
More informationNon-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationPreoperative drainage is always indicated in malignant CBD strictures PRO. Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany
Preoperative drainage is always indicated in malignant CBD strictures PRO Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany Background Jaundice is associated with high perioperative morbidity
More informationBorderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease Matthew HG Katz, MD, Peter WT Pisters, MD, FACS, Douglas B Evans, MD, FACS, Charlotte C Sun, DrPH, MPH, Jeffrey
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationDiagnosis and Prognosis of Pancreatic Cancer
Main Page Risk Factors Reducing Your Risk Screening Symptoms Diagnosis Treatment Overview Chemotherapy Radiation Therapy Surgical Procedures Lifestyle Changes Managing Side Effects Talking to Your Doctor
More informationLong-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Ann Surg Oncol DOI 10.1245/s10434-008-0295-2 ORIGINAL ARTICLE HEPATOBILIARY AND PANCREATIC TUMORS Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma Matthew H.
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationPATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.
PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last
More informationThe Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum
The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY H N SN. WEDGE
More informationPancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh
Pancreatic Cancer The Killer that must be discovered early 27 th June 2015 Dr Alfred Kow Wei Chieh Consultant Department of Surgery Division of HPB Surgery & Liver Transplantation & Assistant Dean (Education)
More informationJ Clin Oncol 24:2897-2902. 2006 by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 18 JUNE 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationHepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationTo Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma
August 2009 To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma Christina Ramirez, Harvard Medical School Year III Gillian Lieberman, MD Agenda
More informationrestricted to certain centers and certain patients, preferably in some sort of experimental trial format.
Managing Pancreatic Cancer, Part 4: Pancreatic Cancer Surgery, Complications, & the Importance of Surgical Volume Dr. Matthew Katz, Surgeon, MD Anderson Cancer Center, Houston, TX I m going to talk a little
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationMedical Marijuana Use in Patients with History of SCCHN Treated with Radiotherapy
HEALTH SERVICES RESEARCH Assessment the Impact of Real-time Tumor Tracking & Reduced Planning Target Volume Margins on Quality-of-Life in Prostate Cancer Patients Treatment with Intensity Modulated Radiotherapy
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationHow To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationPancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy
CASE REPORT Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy Raffaele Dalla Valle 1, Cristina Mancini 2, Pellegrino Crafa 2, Rodolfo Passalacqua 3 1 Department of
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationSBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.
Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationPancreatic Cancer Basics. Meghan McGurk, PA-C, MMSc Physician Assistant Department of Medical Oncology Yale Cancer Center
Pancreatic Cancer Basics Meghan McGurk, PA-C, MMSc Physician Assistant Department of Medical Oncology Yale Cancer Center Case Study Mr.T is a 36 yo male who presented in the fall of 2003, at the age of
More informationGuidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
More informationA Practical Guide to Advances in Staging and Treatment of NSCLC
A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationCurrent and Future Trends in Proton Treatment of Prostate Cancer
Current and Future Trends in Proton Treatment of Prostate Cancer Reinhard W. Schulte Assistant Professor Department of Radiation Medicine Loma Linda University Medical Center Loma Linda, CA, USA Outline
More informationColorectal Cancer Treatment
Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationVascular resection during pancreaticoduodenectomy. Ryan Turley, MD Research Fellow, Duke University
Vascular resection during pancreaticoduodenectomy. Ryan Turley, MD Research Fellow, Duke University Vascular Resection during PD Outline Review of pancreatic adenocarcinoma Role of PD in treatment of pancreatic
More informationTreatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationCancer of the Exocrine Pancreas, Ampulla of Vater and Distal Common Bile Duct Proforma
Cancer of the Exocrine, Ampulla of Vater and Distal Coon Bile Duct Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Sex Male Female Intersex/indeterminate
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationFalse positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationStereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Gastrointestinal Cancer Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable
More informationRESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?
RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which
More informationRe irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
More informationRadioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationManagement of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationSurgical guidelines for the management of breast cancer
Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More informationThe evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of radical laparoscopic hysterectomy for early stage cervical cancer Introduction This overview
More information